A5016003520- Pharmacology and Obesity Treatment
- Diet and metabolism studies
- Diabetes Treatment and Management
- Regulation of Appetite and Obesity
- Eating Disorders and Behaviors
- Obesity, Physical Activity, Diet
- Metabolism, Diabetes, and Cancer
- Adipose Tissue and Metabolism
- Obesity and Health Practices
- Diabetes Management and Research
- COVID-19 Clinical Research Studies
- Biochemical Analysis and Sensing Techniques
- Hyperglycemia and glycemic control in critically ill and hospitalized patients
- Bariatric Surgery and Outcomes
- Pharmaceutical Practices and Patient Outcomes
- Functional Brain Connectivity Studies
- Diet, Metabolism, and Disease
- Child and Adolescent Psychosocial and Emotional Development
- Diabetes Management and Education
- Stress Responses and Cortisol
- Hormonal Regulation and Hypertension
- Transplantation: Methods and Outcomes
- Neuroscience of respiration and sleep
- Dietary Effects on Health
- Muscle metabolism and nutrition
Yale University
2016-2025
Yale Cancer Center
2023-2024
Hacettepe University
2024
Emory University
2024
Finnish Institute for Health and Welfare
2024
University of Helsinki
2024
Obesity Society
2024
Cornell University
2024
Eli Lilly (United States)
2024
Bridgeport Hospital
2021
Obesity is a chronic disease that results in substantial global morbidity and mortality. The efficacy safety of tirzepatide, novel glucose-dependent insulinotropic polypeptide glucagon-like peptide-1 receptor agonist, people with obesity are not known.
Retatrutide (LY3437943) is an agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide 1, and glucagon receptors. Its dose-response relationships with respect to side effects, safety, efficacy for treatment obesity are not known.We conducted a phase 2, double-blind, randomized, placebo-controlled trial involving adults who had body-mass index (BMI, weight in kilograms divided by square height meters) 30 or higher BMI 27 less than plus at least one weight-related...
The emerging obesity epidemic and accompanying health consequences led Obesity Society (TOS) in 2008 to publish a position paper defining as disease. Since then, new information has emerged on the underlying mechanisms leading excess adiposity associated structural, cardiometabolic, functional disturbances. This report presents updated TOS 2018 statement noncommunicable chronic
BackgroundObesity is chronic disease and causal precursor to myriad other conditions, including type 2 diabetes. In an earlier analysis of the SURMOUNT-1 trial, tirzepatide was shown provide substantial sustained reductions in body weight persons with obesity over a 72-week period. Here, we report 3-year safety outcomes its efficacy reducing delaying progression diabetes both prediabetes.MethodsWe performed phase 3, double-blind, randomized, controlled trial which 2539 participants obesity,...
To determine whether semaglutide slows progression of glycemia in people with cardiovascular disease and overweight or obesity but without diabetes.
Obesity is associated with alterations in corticolimbic-striatal brain regions involved food motivation and reward. Stress the presence of cues may each motivate eating engage corticolimibic-striatal neurocircuitry. It unknown how these factors interact to influence responses whether interactions are influenced by obesity, insulin levels, sensitivity. We hypothesized that obese individuals would show greater neurocircuitry after exposure stress activations correlate subjective craving,...
To examine whether baseline chronic stress, morning cortisol, and other appetite-related hormones (leptin, ghrelin, insulin) predict future weight gain food cravings in a naturalistic, longitudinal, 6-month follow-up study.A prospective community cohort of 339 adults (age 29.1 ± 9.0 years; BMI = 26.7 5.4 kg/m2 ; 56.9% female; 70.2% white) completed assessments at follow-up. Fasting blood draws were used to assess cortisol hormone levels baseline. At follow-up, body was measured, the...
This JAMA Insights Clinical Update reviews approaches for managing obesity in adolescents, including behavioral interventions, pharmacotherapy, and surgical with discussion of management considerations unique to this age group.
The aim of this study was to examine how improvement in BMI with the glucagon-like peptide-1 receptor agonist semaglutide translated changes category a post hoc analysis double-blind, phase 3a randomized controlled Semaglutide Treatment Effect People obesity (STEP) TEENS trial.Adolescents received once-weekly subcutaneous 2.4 mg or placebo plus lifestyle intervention, which comprised counseling healthy nutrition and goal 60 minutes moderate- high-intensity physical activity per day....
Abstract Objective Binge‐eating disorder (BED) is a prevalent psychiatric associated with obesity. Few evidence‐based treatments exist for BED, particularly pharmacological options. This study tested the efficacy of naltrexone/bupropion BED. Methods A randomized, double‐blind, placebo‐controlled, 12‐week trial BED and without Eighty‐nine patients (70.8% women, 69.7% White, mean age 45.7 y, BMI 35.1 kg/m 2 , 77.5% ≥ 30 ) were randomized to placebo ( n = 46) or 43), randomization stratified by...
Increased sugar-sweetened beverage consumption has been linked to higher rates of obesity. Using functional MRI, we assessed brain perfusion responses drinking two commonly consumed monosaccharides, glucose and fructose, in obese lean adolescents. Marked differences were observed. In response glucose, adolescents exhibited decreased regions involved executive function (prefrontal cortex [PFC]) increased homeostatic appetite the (hypothalamus). Conversely, demonstrated PFC no change...
OBJECTIVE In the U.S., an astonishing 12.5 million children and adolescents are now obese, predisposing 17% of our nation’s youth to metabolic complications obesity, such as type 2 diabetes (T2D). Adolescent obesity has tripled over last three decades in setting food advertising directed at children. Obese adults exhibit increased brain responses images motivation-reward pathways. These neural alterations may be attributed obesity-related changes, which promote craving high-calorie (HCF)...
The position statement is issued by Obesity Society in response to published literature, as well inquiries made the patients, providers, members, policy makers, and others regarding efficacy of vaccines persons with obesity against SARS-CoV-2, virus that causes COVID-19. has critically evaluated data from peer-reviewed literature briefing documents Emergency Use Authorization applications submitted Pfizer-BioNTech, Moderna, Johnson & Johnson. We conclude these are highly efficacious, their...